Novavax | NVAX - Gross Profit On Sales


Novavax reported $125.04M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 80.75M 8.07M Mar/2026
Agenus USD 33.74M 468K Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Geron USD 50.14M 3.44M Mar/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
MannKind USD 68.33M 9.98M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD -566M 792M Mar/2026
Novartis USD 10.07B 758M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD -248M 11.29B Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026